Shares of Arcus Biosciences Inc. (RCUS) are down more than 30% from their 52-week high of $20.31, recorded last February, and trade around $13.
Arcus is a clinical-stage, global biopharmaceutical company developing combination therapies for cancer. Its investigational drugs in the pipeline include Domvanalimab, Zimberelimab, Casdatifan, Quemliclustat, Etrumadenant, AB598 and AB801.
Zimberelimab, Domvanalimab, Etrumadenant, and Quemliclustat are being co-developed by Arcus and Gilead.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com